News articles about BELLUS Health (OTCMKTS:BLUSF) have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than 6,000 news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BELLUS Health earned a daily sentiment score of -1.00 on their scale. InfoTrie also assigned news stories about the company an news buzz score of 10 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock’s share price in the immediate future.
OTCMKTS:BLUSF traded down $0.02 during trading hours on Thursday, hitting $0.64. The stock had a trading volume of 47,641 shares, compared to its average volume of 97,448. BELLUS Health has a one year low of $0.26 and a one year high of $0.93.
BELLUS Health (OTCMKTS:BLUSF) last posted its quarterly earnings data on Wednesday, August 8th. The company reported ($0.01) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.01. The firm had revenue of $0.01 million for the quarter. BELLUS Health had a negative net margin of 5,071.15% and a negative return on equity of 32.42%.
BELLUS Health Inc, a biopharmaceutical company, engages in developing novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various other partnered clinical-stage drug development programs, including KIACTA, a novel drug candidate for the treatment of patients suffering from active pulmonary sarcoidosis; AMO-01 for Fragile X Syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease.
Featured Story: Stock Split
Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with MarketBeat.com's FREE daily email newsletter.